Swedish Orphan Biovitrum (Sobi) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets. It has also announced a reorganization to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology. The acquisition gives Sobi access to world-class R&D capabilities … Continue reading Sobi acquires emapalumab and related assets from Novimmune